Skip to main content
Premium Trial:

Request an Annual Quote

Former 3rd Millennium Exec to Lead Bioinformatics at Beyond Genomics

NEW YORK, June 8 - Beyond Genomics has hired Eric Neumann, formerly a vice president at 3 rd  Millennium, to the position of vice president of bioinformatics, the company said Friday.

 

At Beyond Genomics, a startup company hoping to commercialize a systems approach to drug discovery, Neumann will be in charge of the scientific and commercial development of the company's bioinformatics platform, according to a statement.

 

Prior to joining Beyond Genomics, Neumann served as vice president of life science informatics at 3 rd Millennium, a bioinformatics consulting group. During his 15 years in bioinformatics, he has also worked at NetGenics and other companies including Bolt, Beranek, and Newman, now a part of Verizon Wireless. Neumann also serves as an advisor to Sun MicroSystem's Life Sciences Open-Platform Initiative.

 

"We are delighted to have a bioinformatics industry veteran like Eric join our team," Stephen Ober, president of Beyond Genomics, said in a statement. "He has a proven track record of developing both models and integrative pathway data solutions that will be the cornerstone of our bioinformatics platform."

 

In May, Beyond Genomics signed a a two-year deal with Elan Pharmaceuticals to search for biomarkers and drug targets associated with Alzheimer's disease, in return for a $5 million equity investment from Elan.

 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.